Burst Biologics Initiates Clinical Study in Foot and Ankle Surgery Patients

Boise, ID, April 25, 2017 (Newswire.com) - Today, Burst Biologics announces their latest IRB approval to begin a multicenter prospective clinical study in Foot and Ankle Surgery patients. Burst Biologics latest product innovation, BioBurst® Fluid, is a cellular tissue product derived from umbilical cord blood (UCB).

This study will include 10 clinical sites throughout the US with an enrollment of 300 patients. This study will include both ankle fusion patients and various osteotomy procedures. The company designed the study parameters broadly in order to evaluate complex surgeries in challenging patient populations. These populations Include patients with high BMI, Charcot, previous non-unions and smokers.

"Registry studies such as this will be an increasingly important component in our health economic system driven by value-based treatment options."

Dr. Roman Burk, Foot and Ankle Surgeon

Dr. Roman Burk, a foot and ankle surgeon stated: “Registry studies such as this will be an increasingly important component in our health economic system driven by value-based treatment options.” CEO Christopher Jones comments: “As a research oriented company we are continuously supporting the efficacy of our products in our state-of-the-art laboratory. This prospective registry is the next step in demonstrating our clinical value in patients undergoing foot and ankle surgical procedures, including the challenging patients.  This study will further demonstrate the value of our products to foot and ankle surgeons as well as third-party payers.”

BioBurst® Fluid is made using the patent pending Progenokine^TM Process. The Progenokine^TM Process is the premier tissue processing methodology used to optimize the support of vasculogenesis and aid in the bone consolidation process.

For more information on this prospective multicenter clinical study please visit: www.clinicaltrials.gov

About Burst Biologics:

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue processing methodologies, all of which is done at the company’s state-of-the-art research facility. For more information about Burst Biologics or its products, please visit its website at: www.BurstBiologics.com

Contact:
Marketing Department
Ryan Sciarrotta 1-888-322-1191
[email protected]

Source: Burst Biologics